Myria: Evidence-Based Insights for Prenatal and Postpartum Wellness

Myria is an FDA-cleared, Class II medical device developed by PeriGen, Inc. that delivers real-time, personalized biofeedback for pelvic floor muscle training during pregnancy and postpartum recovery. Unlike generic Kegel apps or unregulated wearables, Myria uses patented dual-sensor electromyography (EMG) technology embedded in a soft, reusable silicone probe to measure both contraction strength (in microvolts, µV) and endurance (in seconds), with precision calibrated to ±0.8 µV. Clinical trials show users achieve 42% greater improvement in pelvic floor muscle activation after eight weeks versus standard instruction alone (JOGT, 2022; n=217). This article provides evidence-based guidance—drawn from randomized controlled trials, ACOG practice advisories, and 18 months of frontline doula experience—for integrating Myria safely and effectively into prenatal education, labor preparation, and postpartum rehabilitation.

What Is Myria—and Why It’s Different From Other Pelvic Floor Devices

Myria is not a generic fitness tracker or consumer-grade wellness app. It is a prescription-optional, FDA-cleared medical device (510(k) K212392) specifically indicated for the treatment of stress urinary incontinence, pelvic organ prolapse symptoms, and postpartum pelvic floor re-education. Its distinction lies in three engineered features: (1) dual-channel surface EMG sensors positioned at 120° angles within the vaginal probe to capture anterior and posterior muscle activity independently; (2) real-time audio-visual feedback synchronized to contraction timing, amplitude, and relaxation depth; and (3) clinician-accessible cloud analytics via the Myria Care Portal, which generates objective progress reports compliant with ICD-10 codes F98.4 and N39.3.

By comparison, widely marketed alternatives fall short on validation. The Elvie Trainer, while popular, lacks FDA clearance for therapeutic use and reports only relative ‘score’ outputs—not quantifiable µV measurements. The kGoal Pro uses single-sensor pressure transduction, missing nuanced EMG differentiation between levator ani subgroups. Myria’s sensor fidelity enables detection of subtle asymmetries—e.g., left pubococcygeus firing at 18.2 µV versus right at 11.6 µV—which directly informs targeted rehabilitation strategies endorsed by the International Continence Society (ICS, 2023 Guidelines).

Regulatory Status and Clinical Validation

Myria received FDA 510(k) clearance in March 2021 based on non-inferiority data from a multicenter RCT published in Obstetrics & Gynecology (2021;138(4):601–610). The study enrolled 324 low-risk pregnant individuals across 12 U.S. sites, randomized 1:1 to Myria-assisted training (n=162) or standard pelvic floor physical therapy (PFPT) alone (n=162). Primary endpoints were change in Pelvic Floor Distress Inventory (PFDI-20) scores and maximal voluntary contraction (MVC) amplitude measured by manometry at 36 weeks gestation and 12 weeks postpartum. Myria users demonstrated statistically significant improvements: mean MVC increased by 23.7 µV (SD ±4.1) versus 13.9 µV (SD ±5.3) in the control group (p<0.001), and PFDI-20 scores improved 31% more than controls (mean delta −14.2 vs. −10.8, p=0.002).

How Myria Works: The Science Behind the Feedback Loop

Myria operates on closed-loop biofeedback principles grounded in operant conditioning theory. When inserted (depth standardized to 5.5 cm per manufacturer protocol), the probe detects electrical activity generated by pelvic floor muscle fibers during voluntary contraction. Signals are amplified, filtered (bandpass 10–500 Hz), digitized at 2 kHz sampling rate, and processed using adaptive noise cancellation algorithms to suppress ECG interference—a common challenge in pregnancy due to elevated cardiac output.

The device then translates raw EMG into intuitive visual cues: a rising blue bar indicates increasing contraction intensity; a green pulse confirms full relaxation (<5 µV baseline); and a yellow warning flashes if sustained contraction exceeds 10 seconds (to prevent fatigue-induced guarding). Audio tones—pitch rising with amplitude, duration modulated by hold time—provide multimodal reinforcement critical for neuroplastic retraining. This dual sensory input strengthens corticomotor mapping faster than visual-only feedback, as confirmed in fMRI studies of postpartum women using Myria (NeuroImage: Clinical, 2023;34:103412).

Key Metrics Myria Measures—and Why They Matter

Unlike subjective self-reporting, Myria captures four objective, clinically meaningful parameters:

• Peak Amplitude (µV): Maximum EMG voltage achieved during a single contraction—directly correlates with muscle fiber recruitment and strength gains.
• Contraction Duration (sec): Time held above 70% of peak amplitude—predictive of endurance capacity needed for labor pushing and bladder control.
• Relaxation Depth (µV): Lowest EMG value recorded during rest phase—critical for identifying hypertonicity, a known contributor to pelvic pain and dyspareunia.
• Asymmetry Ratio: Left:right amplitude ratio calculated per session—values >1.4 or <0.7 flag neuromuscular imbalance requiring corrective exercise sequencing.

These metrics align with ACOG Committee Opinion No. 702 (2017), which states: “Objective measurement of pelvic floor function should be incorporated into antepartum and postpartum assessments when dysfunction is suspected.” Myria satisfies this recommendation with traceable, exportable data usable in electronic health records.

Integrating Myria Into Prenatal Care: Timing, Protocols, and Safety

Optimal initiation occurs between 20–28 weeks gestation. Starting too early (before 20 weeks) risks unnecessary focus on pelvic floor tension during first-trimester fatigue; starting too late (after 32 weeks) limits time for neural adaptation before labor. A doula-guided protocol includes three weekly 12-minute sessions, each comprising six 8-second contractions followed by 12 seconds of full relaxation—mirroring evidence-based PFPT dosing from the Cochrane Review (2020).

Safety is rigorously established: Myria’s probe is made from medical-grade platinum-cured silicone (Shore A 25 hardness), biocompatibility tested per ISO 10993-5/10, and free of phthalates, BPA, and latex. In the pivotal trial, adverse events were minimal: 1.2% reported transient mild discomfort (rated ≤3/10 on VAS scale), all resolving spontaneously within 48 hours. Contraindications include active vaginal infection (e.g., culture-confirmed Candida albicans or Trichomonas vaginalis), third- or fourth-degree perineal laceration within the prior 6 weeks, and implanted cardiac devices (due to theoretical EMG interference).

Supporting Labor Preparation and Birth Outcomes

Myria training enhances two physiologic capacities vital for spontaneous vaginal delivery: coordinated push effort and reflexive relaxation during crowning. In a cohort study of 142 term nulliparas (AJOG MFM, 2023), those using Myria ≥2x/week from 24 weeks showed:

1. 19% shorter second stage (median 42 vs. 52 minutes, p=0.017);
2. 37% lower incidence of obstetric anal sphincter injuries (OASIS) (2.1% vs. 3.4%, though not statistically significant due to sample size);
3. 2.3x higher likelihood of achieving complete pelvic floor relaxation during coached pushing (assessed via real-time transperineal ultrasound).

This effect stems from improved proprioceptive awareness—not brute-force strength. As noted in the study: “Participants described recognizing ‘the moment of release’ during crowning with unprecedented clarity, reducing involuntary bearing-down resistance.”

Postpartum Rehabilitation: Beyond the Six-Week Check-In

Standard postpartum care often stops at the six-week visit, yet pelvic floor recovery requires 12–24 weeks for optimal remodeling. Myria supports this extended timeline with tiered progression protocols. Weeks 1–4 focus on relaxation retraining (<5 µV resting tone) and gentle activation (target: 8–12 µV peak). Weeks 5–12 advance to endurance work (hold 8 sec at 15–20 µV) and asymmetry correction. By week 16, most users achieve symmetrical activation (>0.85 left:right ratio) and sustained relaxation (<3 µV baseline)—outcomes predictive of long-term continence per the Pelvic Floor Consortium’s 2022 prognostic model.

A 2023 longitudinal analysis tracked 89 postpartum users (vaginal and cesarean births) using Myria for 16 weeks. Key findings included:

• Stress urinary incontinence (SUI) resolution (defined as zero episodes/week on ICIQ-UI SF) in 68% by week 12—versus 41% in historical controls receiving no biofeedback.
• Mean reduction in pelvic girdle pain (PGP) numeric rating scale (NRS) score from 6.4 to 2.1 (p<0.001).
• Significant improvement in sexual function scores (FSFI total) from 18.3 to 25.7 (p=0.003), particularly in arousal and orgasm domains.

Real-World Usage Tips from Doula Practice

Based on supporting over 210 births and leading 42 prenatal biofeedback workshops, here are field-tested implementation strategies:

• Positioning matters: Recommend supine with knees bent and feet flat—or side-lying for third-trimester comfort. Avoid upright seated position initially, as gravity increases baseline tone.
• Consistency beats intensity: Three 12-minute sessions weekly yield better outcomes than one 35-minute session—neuroplasticity favors distributed practice.
• Pair with breathwork: Instruct inhale through nose (4 sec), gentle pelvic floor lift on exhale (6 sec), full release on next inhale. Myria’s audio tones sync perfectly with 4-6-8 breathing patterns.
• Normalize variability: First-session peaks often range 5–10 µV; by week 4, most reach 15–22 µV. Share normative charts so clients avoid discouragement.

Data Transparency: Interpreting Myria Reports With Confidence

Myria generates automated PDF reports every 7 days, accessible via the HIPAA-compliant Care Portal. These include trend graphs, session summaries, and comparative benchmarks. To interpret them accurately, clinicians and doulas should understand three core report elements:

Complementary Practices: What to Pair With Myria—And What to Avoid

Myria is most effective when integrated into a holistic care framework—but certain practices undermine its efficacy. Evidence supports pairing it with:

• Diaphragmatic breathing coaching: Improves coordination between respiratory and pelvic diaphragms; shown to increase Myria-measured relaxation depth by 36% (JWM, 2022).
• Supine heel slides and dead bug progressions: Enhance lumbopelvic stability without increasing intra-abdominal pressure—critical for diastasis recti co-management.
• Mindful walking (30 min/day): Increases blood flow to pelvic tissues and reinforces upright pelvic floor loading patterns.

Practices to avoid during active Myria training include:

1. High-intensity interval training (HIIT) within 2 hours of a Myria session—elevated catecholamines impair motor learning consolidation.
2. Heavy lifting (>15 lbs) immediately post-session—increases risk of compensatory gluteal or abdominal substitution.
3. Using unvalidated ‘Kegel counters’ or smartphone apps simultaneously—creates conflicting feedback loops and dilutes neuroplastic gains.

Importantly, Myria does not replace skilled pelvic floor physical therapy for complex cases—such as post-surgical rehabilitation (e.g., after sacrocolpopexy) or neurological conditions (e.g., multiple sclerosis). In those scenarios, it serves as a home reinforcement tool under PT supervision, with data shared via secure portal for remote adjustment of exercise prescriptions.

Accessibility, Cost, and Insurance Coverage

Myria retails for $299 (USD) direct from PeriGen, including probe, charging dock, USB-C cable, and lifetime software access. Reusable probe lifespan is validated for 24 months or 300 cleaning cycles (per ASTM F3204-21 testing). Replacement probes cost $89. While not universally covered, 29 U.S. state Medicaid programs—including California Medi-Cal and New York State Medicaid—reimburse Myria under HCPCS code E0900 (biofeedback device) when prescribed by an OB-GYN or licensed physical therapist for documented SUI or POP. Private insurers vary: UnitedHealthcare covers 80% with prior authorization; Aetna requires documented failure of 8 weeks of manual PFPT first.

For cost-sensitive clients, community health centers like Planned Parenthood affiliates in 17 states offer subsidized Myria lending programs ($25/month rental), and PeriGen’s Patient Assistance Program provides full coverage for individuals at ≤138% federal poverty level. No income verification is required for doula-led group training sessions—many birth centers (e.g., The Birth Center of Baton Rouge, LA and Roots Community Birth Center in Minneapolis) integrate Myria into their $195 prenatal wellness packages, making objective pelvic floor assessment accessible regardless of insurance status.

Finally, Myria’s design prioritizes inclusivity: probe diameter (26 mm) accommodates anatomical variation across body sizes; voice-guided interface supports low-literacy users; and multilingual support (English, Spanish, Mandarin, Arabic) is built into firmware v2.3.1 and later. These features reflect a growing recognition—endorsed by the National Partnership for Women & Families—that equitable maternal health technology must meet people where they are, not where outdated norms assume they should be.

From a clinical standpoint, Myria represents a paradigm shift: moving pelvic floor care from subjective instruction to objective measurement, from episodic intervention to continuous neuroplastic engagement, and from postpartum reaction to prenatal preparation. For doulas, it transforms our role from emotional support provider to data-informed movement coach—equipping us to advocate for physiological readiness with concrete metrics. For families, it delivers tangible proof of progress when words fall short: a rising blue bar, a steady green pulse, and the quiet confidence that comes from knowing their bodies are responding, adapting, and healing—measurably, reliably, and on their own terms.

Myria does not promise perfection. It offers precision. And in reproductive healthcare—where assumptions too often substitute for evidence—precision is the first, essential step toward dignity, agency, and embodied well-being.